Last reviewed · How we verify
Active (active)
Sisunatovir
Active is a sunscreen agent that works by blocking ultraviolet radiation to prevent sunburn and reduce skin cancer risk. As a topical photoprotective agent, it provides broad-spectrum UV protection when used as directed alongside other sun protection measures, making it a foundational component of comprehensive sun safety strategies.
At a glance
| Generic name | active |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Sisunatovir |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Mechanism of action
Active is a sunscreen that acts as a barrier between your skin and the sun's ultraviolet (UV) rays. When applied to your skin, it either sits on the surface to reflect UV rays away or absorbs into the outer layers to convert those rays into harmless heat. Either way, the goal is the same: stop damaging UV radiation from penetrating deep into your skin where it can cause immediate sunburn and long-term damage. The sun damage that leads to skin cancer and premature aging happens at the cellular level when UV rays penetrate your skin and damage the DNA in your cells. By blocking or absorbing these rays before they go deep, Active prevents this cellular damage from occurring in the first place. This is why consistent use is so important—every time you're exposed to the sun without protection, your cells accumulate more damage. For Active to work effectively, you need to use it correctly and reapply it regularly, especially after swimming or sweating. It's also most effective when combined with other sun protection strategies like wearing protective clothing, seeking shade, and avoiding peak sun hours. Think of it as one important part of a complete sun safety plan rather than a standalone solution.
Approved indications
Pipeline indications
- Respiratory Syncytial Virus Infections — discontinued
Common side effects
Key clinical trials
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) (PHASE1)
- Investigating the Effect of Carpal Tunnel Syndrome on Activity and Participation
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active CI brief — competitive landscape report
- Active updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI